Downregulating viral gene expression: Codon usage bias manipulation for the generation of novel influenza A virus vaccines

Future Virology

Volumn 10, Issue 6, 2015, Pages 715-730

  Baker, Steven F ^a   Nogales, Aitor ^a   Martínez Sobrido, Luis ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

codon deoptimization; codon usage bias; codon pair bias; inactivated influenza vaccines; influenza A virus; influenza reverse genetics; live attenuated influenza virus; recombinant influenza vaccine; synthetic attenuated virus engineering

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; NONSTRUCTURAL PROTEIN 1; NUCLEAR EXPORT PROTEIN; POLYMERASE ACIDIC BASE PROTEIN 1; PROTEIN; SIALIDASE; UNCLASSIFIED DRUG;

CODON USAGE; DOWN REGULATION; GENE EXPRESSION; GENETIC CODE; HUMAN; IMMUNOGENICITY; INFLUENZA A; INFLUENZA A VIRUS; INFLUENZA VACCINATION; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; REVERSE GENETICS; REVIEW; VIRAL GENETICS; VIRUS GENE; VIRUS GENOME; VIRUS PATHOGENESIS;

EID: 84934270384     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.15.31     Document Type: Review

References (99)

1. Shaw ML, Palese P. Orthomyxoviridae: the viruses and their replication. In: Fields Virology (5th edition). Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA (Eds). Lippincott Williams and WIlkins, PA, USA (2007).
2. Resa-Infante P, Jorba N, Coloma R, Ortin J. The influenza virus RNA synthesis machine: advances in its structure and function. RNA Biol. 8(2), 207-215 (2011).
3. Flick R, Neumann G, Hoffmann E, Neumeier E, Hobom G. Promoter elements in the influenza vRNA terminal structure. RNA 2(10), 1046-1057 (1996).
4. Baker SF, Nogales A, Finch C et al. Influenza A and B virus intertypic reassortment through compatible viral packaging signals. J. Virol. 88(18), 10778-10791 (2014).
5. Hutchinson EC, Von Kirchbach JC, Gog JR, Digard P. Genome packaging in influenza A virus. J. Gen. Virol. 91(Pt 2), 313-328 (2010).
6. Varghese JN, Mckimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14(3), 327-332 (1992).
7. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 25(39-40), 6852-6862 (2007).
8. Tong S, Zhu X, Li Y et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 9(10), e1003657 (2013).
9. Wise HM, Hutchinson EC, Jagger BW et al. Identification of a novel splice variant form of the influenza A virus M2 ion channel with an antigenically distinct ectodomain. PLoS Pathog. 8(11), e1002998 (2012).
10. Paterson D, Fodor E. Emerging roles for the influenza A virus nuclear export protein (NEP). PLoS Pathog. 8(12), e1003019 (2012).
11. Hai R, Schmolke M, Varga ZT et al. PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J. Virol. 84(9), 4442-4450 (2010).
12. Jagger BW, Wise HM, Kash JC et al. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Science 337(6091), 199-204 (2012).
13. Wise HM, Foeglein A, Sun J et al. A complicated message: identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA. J. Virol. 83(16), 8021-8031 (2009).
14. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89(Pt 1), 1-47 (2008).
15. Hale BG. Conformational plasticity of the influenza A virus NS1 protein. J. Gen. Virol. 95(Pt 10), 2099-2105 (2014).
16. Hale BG, Randall RE, Ortin J, Jackson D. The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 89(Pt 10), 2359-2376 (2008).
17. Richt JA, Garcia-Sastre A. Attenuated influenza virus vaccines with modified NS1 proteins. Curr. Top Microbiol. Immunol. 333, 177-195 (2009).
18. Bullido R, Gomez-Puertas P, Saiz MJ, Portela A. Influenza A virus NEP (NS2 protein) downregulates RNA synthesis of model template RNAs. J. Virol. 75(10), 4912-4917 (2001).
19. Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25(27), 5086-5096 (2007).
20. Girard MP, Cherian T, Pervikov Y, Kieny MP. A review of vaccine research and development: human acute respiratory infections. Vaccine 23(50), 5708-5724 (2005).
21. Smith GJ, Vijaykrishna D, Bahl J et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459(7250), 1122-1125 (2009).
22. Kilbourne ED. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 12(1), 9-14 (2006).
23. Xu X, Lindstrom SE, Shaw MW et al. Reassortment and evolution of current human influenza A and B viruses. Virus Res. 103 (1-2), 55-60 (2004).
24. WHO: Influenza (Seasonal) Fact sheet No. 211. www.who.int/mediacentre/factsheets/fs211/en
25. Garten RJ, Davis CT, Russell CA et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325(5937), 197-201 (2009).
26. Maines TR, Jayaraman A, Belser JA et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325(5939), 484-487 (2009).
27. Lynch JP 3rd, Walsh EE. Influenza: evolving strategies in treatment and prevention. Semin. Respir. Crit. Care Med. 28(2), 144-158 (2007).
28. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12(1), 36-44 (2012).
29. Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356(7), 685-696 (2007).
30. Belshe RB, Newman FK, Wilkins K et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25(37-38), 6755-6763 (2007).
31. Pronker ES, Claassen E, Osterhaus AD. Development of new generation influenza vaccines: recipes for success? Vaccine 30(51), 7344-7347 (2012).
32. Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir. Viruses 2(6), 211-219 (2008).
33. Baker SF, Guo H, Albrecht RA, Garcia-Sastre A, Topham DJ, Martinez-Sobrido L. Protection against lethal influenza with a viral mimic. J. Virol. 87(15), 8591-8605 (2013).
34. Sun W. Approval Letter-Fluarix Quadrivalent (BL 125127/513). U.S. Food and 976 Drug Administration (FDA). www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm332484.htm
35. Belongia EA, Kieke BA, Donahue JG et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J. Infect. Dis. 199(2), 159-167 (2009).
36. Tlaxca JL, Ellis S, Remmele RL Jr. Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges. Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2014.10.002 (2014) (Epub ahead of print).
37. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu. Rev. Med. 64, 189-202 (2013).
38. Gorse GJ, Belshe RB, Munn NJ. Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest 100(4), 977-984 (1991).
39. Greenhawt MJ. Influenza vaccination in asthmatic patients. J. Allergy. Clin. Immunol. 133(4), 1233-1234 (2014).
40. Jin H, Zhou H, Lu B, Kemble G. Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60. J. Virol. 78(2), 995-998 (2004).
41. Treanor JJ, Schiff GM, Hayden FG et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 297(14), 1577-1582 (2007).
42. Ohmit SE, Victor JC, Rotthoff JR et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 355(24), 2513-2522 (2006).
43. Kieny MP, Costa A, Hombach J et al. A global pandemic influenza vaccine action plan. Vaccine 24(40-41), 6367-6370 (2006).
44. Friede M, Palkonyay L, Alfonso C et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 29 (Suppl. 1), A2-A7 (2011).
45. Perdue ML, Arnold F, Li S et al. The future of cell culture-based influenza vaccine production. Expert Rev. Vaccines 10(8), 1183-1194 (2011).
46. Grantham R, Gautier C, Gouy M. Codon frequencies in 119 individual genes confirm consistent choices of degenerate bases according to genome type. Nucleic Acids Res. 8(9), 1893-1912 (1980).
47. Kanaya S, Yamada Y, Kinouchi M, Kudo Y, Ikemura T. Codon usage and tRNA genes in eukaryotes: correlation of codon usage diversity with translation efficiency and with CG-dinucleotide usage as assessed by multivariate analysis. J. Mol. Evol. 53 (4-5), 290-298 (2001).
48. Knight RD, Freeland SJ, Landweber LF. A simple model based on mutation and selection explains trends in codon and amino-acid usage and GC composition within and across genomes. Genome Biol. 2(4), RESEARCH0010, 1-13 (2001).
49. Lavner Y, Kotlar D. Codon bias as a factor in regulating expression via translation rate in the human genome. Gene 345(1), 127-138 (2005).
50. Codon Usage Database. www.kazusa.or.jp/codon
51. Burns CC, Shaw J, Campagnoli R et al. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J. Virol. 80(7), 3259-3272 (2006).
52. Coleman JR, Papamichail D, Skiena S, Futcher B, Wimmer E, Mueller S. Virus attenuation by genome-scale changes in codon pair bias. Science 320(5884), 1784-1787 (2008).
53. Goni N, Iriarte A, Comas V et al. Pandemic influenza A virus codon usage revisited: biases, adaptation and implications for vaccine strain development. Virol. J. 9, 263 (2012).
54. Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J. Virol. 80(19), 9687-9696 (2006).
55. Nogales A, Baker SF, Ortiz-Riano E, Dewhurst S, Topham DJ, Martinez-Sobrido L. Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. J. Virol. 88(18), 10525-10540 (2014).
56. Plotkin JB, Dushoff J. Codon bias and frequency-dependent selection on the hemagglutinin epitopes of influenza A virus. Proc. Natl Acad. Sci. USA 100(12), 7152-7157 (2003).
57. Mueller S, Coleman JR, Papamichail D et al. Live attenuated influenza virus vaccines by computer-aided rational design. Nat. Biotechnol. 28(7), 723-726 (2010).
58. Barrai I, Scapoli C, Barale R, Volinia S. Oligonucleotide correlations between infector and host genomes hint at evolutionary relationships. Nucleic Acids Res. 18(10), 3021-3025 (1990).
59. Duret L. Evolution of synonymous codon usage in metazoans. Curr. Opin. Genet. Dev. 12(6), 640-649 (2002).
60. Karlin S, Blaisdell BE, Schachtel GA. Contrasts in codon usage of latent versus productive genes of Epstein-Barr virus: data and hypotheses. J. Virol. 64(9), 4264-4273 (1990).
61. Zhou J, Liu WJ, Peng SW, Sun XY, Frazer I. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J. Virol. 73(6), 4972-4982 (1999).
62. Bahir I, Fromer M, Prat Y, Linial M. Viral adaptation to host: a proteome-based analysis of codon usage and amino acid preferences. Mol. Syst. Biol. 5, 311 (2009).
63. Meng J, Lee S, Hotard AL, Moore ML. Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes. MBio 5(5), e01704-e01714 (2014).
64. Yang C, Skiena S, Futcher B, Mueller S, Wimmer E. Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice. Proc. Natl Acad. Sci. USA 110(23), 9481-9486 (2013).
65. Le Nouen C, Brock LG, Luongo C et al. Attenuation of human respiratory syncytial virus by genome-scale codon-pair deoptimization. Proc. Natl Acad. Sci. USA 111(36), 13169-13174 (2014).
66. Hall MN, Gabay J, Debarbouille M, Schwartz M. A role for mRNA secondary structure in the control of translation initiation. Nature 295(5850), 616-618 (1982).
67. Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725), 1545-1555 (2010).
68. Hall CB, Weinberg GA, Blumkin AK et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 132(2), e341-e348 (2013).
69. Murakami S, Horimoto T, Ito M et al. Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion. J. Virol. 86(3), 1405-1410 (2012).
70. Neumann G, Watanabe T, Ito H et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl Acad. Sci. USA 96(16), 9345-9350 (1999).
71. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J. Virol. 73(11), 9679-9682 (1999).
72. Neumann G, Kawaoka Y. Generation of influenza A virus from cloned cDNAs-historical perspective and outlook for the new millenium. Rev. Med. Virol. 12(1), 13-30 (2002).
73. Hoffmann E, Neumann G, Hobom G, Webster RG, Kawaoka Y. "Ambisense" approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template. Virology 267(2), 310-317 (2000).
74. Hussain AI, Cordeiro M, Sevilla E, Liu J. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 28(22), 3848-3855 (2010).
75. Ozawa M, Fujii K, Muramoto Y et al. Contributions of two nuclear localization signals of influenza A virus nucleoprotein to viral replication. J. Virol. 81(1), 30-41 (2007).
76. Muramoto Y, Takada A, Fujii K et al. Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into influenza A virions. J. Virol. 80(5), 2318-2325 (2006).
77. Marsh GA, Hatami R, Palese P. Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J. Virol. 81(18), 9727-9736 (2007).
78. Fujii Y, Goto H, Watanabe T, Yoshida T, Kawaoka Y. Selective incorporation of influenza virus RNA segments into virions. Proc. Natl Acad. Sci. USA 100(4), 2002-2007 (2003).
79. Fujii K, Fujii Y, Noda T et al. Importance of both the coding and the segment-specific noncoding regions of the influenza A virus NS segment for its efficient incorporation into virions. J. Virol. 79(6), 3766-3774 (2005).
80. Ozawa M, Maeda J, Iwatsuki-Horimoto K et al. Nucleotide sequence requirements at the 5' end of the influenza A virus M RNA segment for efficient virus replication. J. Virol. 83(7), 3384-3388 (2009).
81. Thangavel RR, Bouvier NM. Animal models for influenza virus pathogenesis, transmission, and immunology. J. Immunol. Methods 410, 60-79 (2014).
82. Epstein SL. Control of influenza virus infection by immunity to conserved viral features. Expert Rev. Anti. Infect. Ther. 1(4), 627-638 (2003).
83. Influenza Research Database. www.fludb.org
84. Chua MA, Schmid S, Perez JT, Langlois RA, Tenoever BR. Influenza A virus utilizes suboptimal splicing to coordinate the timing of infection. Cell. Rep. 3(1), 23-29 (2013).
85. Hutchinson EC, Charles PD, Hester SS et al. Conserved and host-specific features of influenza virion architecture. Nat. Commun. 5, 4816 (2014).
86. Turrell L, Lyall JW, Tiley LS, Fodor E, Vreede FT. The role and assembly mechanism of nucleoprotein in influenza A virus ribonucleoprotein complexes. Nat. Commun. 4, 1591 (2013).
87. Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19(13-14), 1732-1737 (2001).
88. Martinez-Sobrido L, Cadagan R, Steel J et al. Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J. Virol. 84(4), 2157-2163 (2010).
89. Nayak DP, Hui EK, Barman S. Assembly and budding of influenza virus. Virus Res. 106(2), 147-165 (2004).
90. Krammer F, Palese P, Steel J. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr. Top. Microbiol. Immunol. 386, 301-321 (2015).
91. Gulati U, Hwang CC, Venkatramani L et al. Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). J. Virol. 76(23), 12274-12280 (2002).
92. Kochs G, Garcia-Sastre A, Martinez-Sobrido L. Multiple anti-interferon actions of the influenza A virus NS1 protein. J. Virol. 81(13), 7011-7021 (2007).
93. Mibayashi M, Martinez-Sobrido L, Loo YM, Cardenas WB, Gale M Jr, Garcia-Sastre A. Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J. Virol. 81(2), 514-524 (2007).
94. Steidle S, Martinez-Sobrido L, Mordstein M et al. Glycine 184 in nonstructural protein NS1 determines the virulence of influenza A virus strain PR8 without affecting the host interferon response. J. Virol. 84(24), 12761-12770 (2010).
95. Basler CF, Garcia-Sastre A. Viruses and the type I interferon antiviral system: induction and evasion. Int. Rev. Immunol. 21 (4-5), 305-337 (2002).
96. Dove BK, Surtees R, Bean TJ et al. A quantitative proteomic analysis of lung epithelial (A549) cells infected with 2009 pandemic influenza A virus using stable isotope labelling with amino acids in cell culture. Proteomics 12(9), 1431-1436 (2012).
97. Wong EH, Smith DK, Rabadan R, Peiris M, Poon LL. Codon usage bias and the evolution of influenza A viruses. Codon usage biases of influenza virus. BMC Evol. Biol. 10, 253 (2010).
98. Yoon SW, Webby RJ, Webster RG. Evolution and ecology of influenza A viruses. Curr. Top Microbiol. Immunol. 385, 359-375 (2014).
99. Qi X, Jiang D, Wang H et al. Calculating the burden of disease of avian-origin H7N9 infections in China. BMJ Open 4(1), e004189 (2014).